在高级阶段的经典霍奇金淋巴瘤中,Nivolumab+AVD
Alex F Herrera1, Michael LeBlanc1, Sharon M Castellino1
1From City of Hope Comprehensive Cancer Center, Duarte (A.F.H., M.G.M., J.Y.S.), University of California Davis Comprehensive Cancer Center, Sacramento (J.M.T.), and Children's Hospital Los Angeles, Los Angeles (C.F., A.D., A.K.) - all in California; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, (M.L., H.L.) and Seattle Children's Hospital (A.L.) - both in Seattle; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta (S.M.C.), and Winship Cancer Institute and Emory University Hospital (K.A.B.), Atlanta; Weill Cornell Medicine (S.C.R., J.P.L.), Memorial Sloan Kettering Cancer Center (P.T.), and New York University Langone (L.K.S.), New York, Wilmot Cancer Institute, University of Rochester, Rochester (C.C., L.S.C., J.W.F.), and Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo (K.M.K.) - all in New York; Rutgers Cancer Institute of New Jersey, New Brunswick (A.M.E.); McGill University Health Centre, Montreal (K.D.), and SickKids Hospital (Angela Punnett) and Princess Margaret Cancer Centre (D.H., Anca Prica, M.C.), Toronto - all in Canada; Reid R. Sacco AYA Cancer Program, Tufts Medical Center (S.K.P.), and Dana-Farber Cancer Institute (M.A.S.) - both in Boston; M.D. Anderson Cancer Center, Houston (S.A.), and University of Texas Health Science Center at San Antonio, San Antonio (S.K.) - both in Texas; Siteman Cancer Center, Washington University, St. Louis (N.L.B., B.K.); Medical University of South Carolina, Charleston (B.T.H.), and Prisma Health Cancer Institute - Eastside, Greenville (S.C.) - both in South Carolina; Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC (R.J.); Moffitt Cancer Center, Tampa (H.S.), and Sylvester Comprehensive Cancer Center, University of Miami, Miami (C.M.) - both in Florida; Huntsman Cancer Institute, University of Utah, Salt Lake City (B.H.); University of Alabama at Birmingham, Birmingham (G.G.); Illinois CancerCare, Peoria (P.K.), and University of Chicago, Chicago (S.M.S.); Cancer and Hematology Centers of Western Michigan, Grand Rapids (B.B.), and University of Michigan, Ann Arbor (A.M.P.); the Department of Hematology and Oncology, Geisinger Community Medical Center, Scranton, PA (N.S.); Fairview Ridges Hospital, Minnesota Oncology, Burnsville (A.S.); SWOG Cancer Research Network, Teaneck, NJ (H.D.); and the National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD (R.F.L.).
尼沃卢马布加化疗 (N+AVD) 显著改善了高级霍奇金病的无进展生存率.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 血液学 血液学 血液学
背景情况:
- 布伦图西马布维多丁 (BV) 改善了高级经典霍奇金淋巴瘤的结果,但具有毒性作用和复发的挑战.
- 编程死亡1 (PD-1) 阻塞在霍奇金淋巴瘤中显示出有效性,包括在未经治疗的患者中.
- 巩固性辐射在接受BV治疗的儿科患者中很常见.
研究的目的:
- 为了比较N+AVD与BV+AVD在新诊断的高级阶段经典霍奇金淋巴瘤中的疗效和安全性.
- 在3期随机试验中评估无进展生存率作为主要终点.
主要方法:
- 一个第三阶段,多中心,开放标签,随机试验.
- 患有新诊断的III/IV期霍奇金淋巴瘤的患者 (≥12岁) 被分配到N+AVD或BV+AVD.
- 无进展生存被定义为疾病进展或死亡的时间.
主要成果:
- 与BV+AVD相比,N+AVD显著改善了无进展生存率 (危险比,0.45;95% CI,0.30至0.65).
- 两年无进展生存率为N+AVD的92%与BV+AVD的83%相比.
- N+AVD显示出更好的副作用概况,治疗中断较少.
结论:
- 尼沃卢马布加化学疗法 (N+AVD) 在高级阶段的经典霍奇金淋巴瘤中优于布伦图西马布维多丁加化学疗法 (BV+AVD).
- 在这种患者群体中,N+AVD提供了改善的无进展生存率和更好的安全概况.
- 这种疗法代表了新诊断的霍奇金淋巴瘤治疗的重大进展.
更多相关视频
相关概念视频
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...


